GlassScriptPhysician profile
Manman Zhang
NPI 1295387991
$3,502.07
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $739 · 2022: $985 · 2023: $1,062 · 2024: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,778.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $585.97 | 2021-2024 | Jardiance, Mounjaro, Emgality |
| Abbvie INC. | $582.75 | 2022-2024 | |
| Gilead Sciences, INC. | $439.07 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.05 | 2021-2024 | Tradjenta, Jardiance, Synjardy |
| Novo Nordisk INC | $236.16 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Viiv Healthcare Company | $190.78 | 2022-2024 | Apretude |
| Pfizer INC. | $188.27 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $181.35 | 2021-2024 | Breztri, Airsupra, Fasenra |
| Bayer Healthcare Pharmaceuticals INC. | $120.96 | 2022-2024 | |
| Glaxosmithkline, LLC. | $90.41 | 2021-2024 | Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $71.94 | 2022-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $67.00 | 2023 | Quviviq |
| Lundbeck LLC | $59.68 | 2022-2023 | Rexulti |
| Esperion Therapeutics, INC. | $58.06 | 2021-2023 | Nexletol |
| Neurocrine Biosciences, INC. | $57.48 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $55.13 | 2021 | |
| Shield Therapeutics INC | $47.13 | 2022-2024 | Accrufer |
| Astellas Pharma US INC | $46.60 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.39 | 2021-2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $35.88 | 2021-2022 | |
| Exact Sciences Corporation | $32.77 | 2023 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.14 | 2022 | |
| Mylan Specialty L.P. | $16.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manman Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.